These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31677321)

  • 1. Clinical predictors of progression and clearance of low-level CMV DNAemia in solid organ transplant recipients.
    Natori Y; Alghamdi A; Husain S; Rotstein C; Selzner N; Tikkanen J; Schiff J; Humar A; Kumar D
    Transpl Infect Dis; 2020 Feb; 22(1):e13207. PubMed ID: 31677321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes.
    Talaya A; Giménez E; Piñana JL; Albert E; Hernández-Boluda JC; Pérez A; Torres I; Solano C; Navarro D
    J Med Virol; 2019 Jun; 91(6):1128-1135. PubMed ID: 30735250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Tasso+ blood self-collection device for quantitation of plasma cytomegalovirus (CMV) DNAemia in adult solid organ transplant recipients (SOTr).
    Phan T; Kumar L; Woo M; Sadowska-Klasa A; Castor J; Pepper G; Fisher CE; Limaye AP
    Microbiol Spectr; 2024 Jul; 12(7):e0003024. PubMed ID: 38771037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus surveillance after antiviral prophylaxis in CMV mismatched transplant patients: Does recurrent cytomegalovirus DNAemia impact patient survival?
    Fernández-García OA; Hernandez C; Robbins M; Kabbani D; Doucette K; Cervera C
    Transpl Infect Dis; 2024 Aug; 26(4):e14292. PubMed ID: 38728099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J; Gatault P; Sautenet B; Gaudy-Graffin C; Beby-Defaux A; Thierry A; Essig M; Halimi JM; Munteanu E; Alain S; Buchler M
    J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
    Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
    Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.
    Vinuesa V; Bracho MA; Albert E; Solano C; Torres-Puente M; Giménez E; González-Candelas F; Navarro D
    J Gen Virol; 2017 Oct; 98(10):2530-2542. PubMed ID: 28874227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.
    Solano C; Giménez E; Piñana JL; Albert E; Vinuesa V; Hernández-Boluda JC; Amat P; Navarro D
    Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28471073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.
    Huntley D; Giménez E; Pascual MJ; Hernández-Boluda JC; Gago B; Vázquez L; Piñana JL; García M; Pérez A; Serrano D; Hernández M; Albert E; Solano C; Navarro D
    Transpl Infect Dis; 2020 Feb; 22(1):e13206. PubMed ID: 31677215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Duration and Degree of Cytomegalovirus DNAemia Observed With Two Standardized Quantitative Nucleic Acid Tests and Implications for Clinical Care.
    Meesing A; Germer JJ; Yao JD; Gartner ML; Digmann BJ; Razonable RR
    J Infect Dis; 2020 Jan; 221(2):251-255. PubMed ID: 31504626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB; Phadke VK; Pouch SM; Mehta AK; Karadkhele G; Larsen CP; Woodworth MH
    Clin Transplant; 2024 Oct; 38(10):e15480. PubMed ID: 39427300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.
    Muñoz-Cobo B; Solano C; Costa E; Bravo D; Clari MÁ; Benet I; Remigia MJ; Montoro J; Navarro D
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1602-11. PubMed ID: 21871245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
    Tan SK; Waggoner JJ; Pinsky BA
    J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
    Lisboa LF; Preiksaitis JK; Humar A; Kumar D
    Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
    Beechar VB; Pouch SM; Phadke VK; Karadkhele G; Larsen CP; Woodworth MH
    Transpl Infect Dis; 2024 Feb; 26(1):e14219. PubMed ID: 38158932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and Chronic Changes in Gene Expression After CMV DNAemia in Kidney Transplant Recipients.
    Ahn R; Schaenman J; Qian Z; Pickering H; Groysberg V; Rossetti M; Llamas M; Hoffmann A; Gjertson D; Deng M; Bunnapradist S; Reed EF;
    Front Immunol; 2021; 12():750659. PubMed ID: 34867983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cytomegalovirus "Blips" in high-risk kidney/kidney-pancreas transplant recipients.
    Payne AT; Lindner BK; Gilbert AJ; Kumar RN; Thomas BS; Timpone JG
    Transpl Infect Dis; 2022 Apr; 24(2):e13789. PubMed ID: 35014122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
    Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
    Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study.
    Fernández-García OA; García-Juárez I; Belaunzarán-Zamudio PF; Vilatoba M; Wisniowski-Yáñez A; Salomón-Ávila J; Bobadilla-Del-Valle M; Sifuentes-Osornio J; Cuellar-Rodríguez JM
    BMC Infect Dis; 2022 Feb; 22(1):155. PubMed ID: 35164684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.